Last reviewed · How we verify
Injections of tildrakizumab
Injections of tildrakizumab is a IL-23 inhibitor monoclonal antibody Small molecule drug developed by Sun Pharmaceutical Industries Limited. It is currently FDA-approved for Moderate to severe plaque psoriasis, Psoriatic arthritis.
Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin.
Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis.
At a glance
| Generic name | Injections of tildrakizumab |
|---|---|
| Sponsor | Sun Pharmaceutical Industries Limited |
| Drug class | IL-23 inhibitor monoclonal antibody |
| Target | IL-23 (interleukin-23), p19 subunit |
| Modality | Small molecule |
| Therapeutic area | Immunology/Dermatology |
| Phase | FDA-approved |
Mechanism of action
Tildrakizumab binds to the p19 subunit of IL-23, a key cytokine involved in the pathogenesis of psoriasis and other inflammatory skin conditions. By inhibiting IL-23 signaling, the drug suppresses the differentiation and activation of pathogenic T cells, particularly Th17 cells, thereby reducing skin inflammation and improving clinical outcomes in psoriatic disease.
Approved indications
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Nasopharyngitis
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. (PHASE3)
- Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) (PHASE3)
- Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis (PHASE3)
- Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) (PHASE3)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab. (PHASE2, PHASE3)
- Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo (EARLY_PHASE1)
- Effects of Tildrakizumab on Epigenetic Age (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injections of tildrakizumab CI brief — competitive landscape report
- Injections of tildrakizumab updates RSS · CI watch RSS
- Sun Pharmaceutical Industries Limited portfolio CI
Frequently asked questions about Injections of tildrakizumab
What is Injections of tildrakizumab?
How does Injections of tildrakizumab work?
What is Injections of tildrakizumab used for?
Who makes Injections of tildrakizumab?
What drug class is Injections of tildrakizumab in?
What development phase is Injections of tildrakizumab in?
What are the side effects of Injections of tildrakizumab?
What does Injections of tildrakizumab target?
Related
- Drug class: All IL-23 inhibitor monoclonal antibody drugs
- Target: All drugs targeting IL-23 (interleukin-23), p19 subunit
- Manufacturer: Sun Pharmaceutical Industries Limited — full pipeline
- Therapeutic area: All drugs in Immunology/Dermatology
- Indication: Drugs for Moderate to severe plaque psoriasis
- Indication: Drugs for Psoriatic arthritis
- Compare: Injections of tildrakizumab vs similar drugs
- Pricing: Injections of tildrakizumab cost, discount & access